Mineralys Therapeutics, Inc. to Post FY2024 Earnings of ($2.04) Per Share, Lifesci Capital Forecasts (NASDAQ:MLYS)

Mineralys Therapeutics, Inc. (NASDAQ:MLYSFree Report) – Investment analysts at Lifesci Capital issued their FY2024 earnings estimates for shares of Mineralys Therapeutics in a research note issued to investors on Tuesday, March 26th. Lifesci Capital analyst R. Katkhuda anticipates that the company will earn ($2.04) per share for the year. Lifesci Capital currently has a “Outperform” rating on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($2.44) per share.

Mineralys Therapeutics Stock Up 1.0 %

Shares of NASDAQ:MLYS opened at $12.91 on Thursday. The firm has a market cap of $640.72 million and a price-to-earnings ratio of -6.46. Mineralys Therapeutics has a 12 month low of $5.85 and a 12 month high of $17.70. The company’s fifty day simple moving average is $13.34 and its 200 day simple moving average is $10.13.

Mineralys Therapeutics (NASDAQ:MLYSGet Free Report) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.61) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.24.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. CWM LLC acquired a new stake in shares of Mineralys Therapeutics during the 3rd quarter worth about $25,000. PNC Financial Services Group Inc. lifted its holdings in Mineralys Therapeutics by 17,821.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company’s stock worth $35,000 after purchasing an additional 4,099 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Mineralys Therapeutics in the 4th quarter valued at $41,000. New York State Common Retirement Fund acquired a new stake in shares of Mineralys Therapeutics during the first quarter worth $53,000. Finally, California State Teachers Retirement System acquired a new stake in Mineralys Therapeutics in the 1st quarter worth about $70,000. 84.46% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Mineralys Therapeutics

In other Mineralys Therapeutics news, major shareholder Samsara Biocapital Gp, Llc purchased 555,555 shares of the business’s stock in a transaction on Monday, February 12th. The shares were purchased at an average cost of $13.50 per share, with a total value of $7,499,992.50. Following the transaction, the insider now directly owns 5,074,916 shares of the company’s stock, valued at approximately $68,511,366. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

About Mineralys Therapeutics

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.

Recommended Stories

Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.